Ipamorelin + Tesamorelin Blend for Fat Loss
Investigational blend pairing a clean GHRP (ipamorelin) with a stable GHRH (tesamorelin).
Why Ipamorelin + Tesamorelin Blend for fat loss?
Compounding pharmacies began offering ipamorelin + tesamorelin blends in 2024-2025 after the FDA tightened on CJC-1295. Tesamorelin is FDA-approved (Egrifta) for HIV-associated lipodystrophy, providing a stable GHRH backbone with documented visceral-fat reduction; ipamorelin contributes a clean ghrelin-mimetic pulse. Limited combination-trial data exists.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Ipamorelin + Tesamorelin Blend fits this goal because its category (Performance) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Visceral fat targeting via tesamorelin
Reference dosing by bodyweight
Anchored to the most-cited research dose (1200 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 748–1012 mcg |
| 60–75 kg / 132–165 lb | 918–1242 mcg |
| 75–90 kg / 165–198 lb | 1122–1518 mcg |
| 90–105 kg / 198–231 lb | 1326–1794 mcg |
| >105 kg / >231 lb | 1530–2070 mcg |
Side effects to weigh against fat loss benefit
- Injection-site reactions
- Possible water retention
- Insulin resistance with chronic use
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.